Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed is a clinical-stage biotechnology company with a promising product candidate, Neflamapimod, which has shown potential in treating age-related neurologic disorders through its ability to improve synaptic dysfunction. The company plans to initiate a global Phase 3 trial in 2026 and expects to release top-line data in 2028, potentially leading to a market entry in 2029. The drug's Fast Track status and the severity of the unmet need in DLB, combined with promising MRI and biomarker data, make CervoMed a strong investment opportunity for the future.

Bears say

CervoMed is poised for significant growth with upcoming catalysts such as a financing for Phase 3 trials, regulatory approvals, and additional data supporting the potential of Neflamapimod to treat age-related neurologic disorders. With DLB being the second most common progressive dementia and the lack of approved treatments, CervoMed's development of a potentially first-in-class therapeutic presents a unique opportunity. However, delays in regulatory interactions and uncertainties in trial timelines may impact the company's ability to successfully advance its program toward pivotal development.

CervoMed Inc (CRVO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.